Malaria vaccine Quilimmune - Antigenics

Drug Profile

Malaria vaccine Quilimmune - Antigenics

Alternative Names: Quilimmune-M

Latest Information Update: 14 Dec 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Antigenics; Instituto de Immunologia
  • Developer Instituto de Immunologia
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Falciparum malaria

Most Recent Events

  • 14 Dec 2000 Discontinued-I for Falciparum malaria in Colombia (Unknown route)
  • 01 Dec 2000 Aquila Biopharmaceuticals has been acquired by Antigenics
  • 12 Mar 1999 New profile, split from generic Malaria vaccine profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top